Biopsy Needle Market Size, Share, and Trends 2024 to 2034

Biopsy Needle Market Size to Reach USD 2.82 Bn by 2034

The global biopsy needle market size was USD 1.30 billion in 2023, accounted for USD 1.39 billion in 2024, and is expected to reach around USD 2.82 billion by 2034, expanding at a CAGR of 7.3% from 2024 to 2034. The North America biopsy needle market size reached USD 520 million in 2023. The rising cancer incidence is expected to drive the growth of the market.

Biopsy Needle Market Key Takeaways

• North America dominated the global biopsy needle market with the largest market share of 40% in 2023.
• Asia Pacific is considered to register the fastest growth with a significant CAGR during the forecast period.
• By-product, the biopsy needle guns segment has held the largest share of 62% in 2023.
• By application, the cancer segment accounted largest market share of 46% in 2023.
• By end-user, the hospitals segment has registered the largest market share of 58% in 2023.

U.S. Biopsy Needle Market Size and Growth 2024 to 2034

The U.S. biopsy needle market size was estimated at USD 360 million in 2023 and is predicted to be worth around USD 810 million by 2034, at a CAGR of 7.6% from 2024 to 2034.

North America dominated the global biopsy needle market with the largest share in 2023. The increasing number of cancer incidences in North American countries has resulted in the increasing demand for biopsy needles. The United States is a leading market player due to the presence of key market companies and the advanced infrastructure. The FDA has been focusing on increasing the medical device approvals which may help the region to continue its dominance throughout the forecast period. The region is reported to witness a higher number of prostate cancer patients which is increasing the need for convenient diagnostic procedures. Many companies are increasing the healthcare expenditure which is leading towards more opportunities in the upcoming years.

Europe held a considerable share of the biopsy needle market in 2023. The region is considered to be the home for elderly people which is increasing the demand for more treatments. The increasing technologies and the involvement of new market companies are boosting the sales of biopsy needles in the region which is considered to drive the market growth within the next 10 years.

Asia Pacific is expected to register the fastest growth due to the emergence of new companies in countries like India, Japan, and China. The region stands out as the most populated in the world which increases the risk of chronic diseases due to changing lifestyle dynamics. The developing countries are more focused on expanding their healthcare infrastructure by increasing the expenditure and R&D activities. This will help to introduce new medical technologies which are more convenient and reliable. The collaborations between cross-industry players is likely to expand the market globally.

Market Overview

A biopsy needle is a thin hollow medical tool used to extract the body tissues for diagnosing purposes. The needle is attached to a syringe or a biopsy gun which further is inserted in the body for diagnosing. It is guided to the targeted area like an organ or lump using various techniques like X-ray or Ultrasound. Further, the sample is obtained by cutting the area or by suction. The extracted tissue from the organ is further examined by using a microscope to detect the present disease or abnormality. Sometimes tests like Computerized Tomography (CT) scans are conducted to ensure accuracy in locating the area to be biopsied.

Biopsy Needle Market Growth Factors

• The rising incidence of cancer around the globe is driving the growth of the biopsy needle market. Cancer is the second most common disease leading to death.
•  The increasing geriatric population is leading to more chronic medical conditions which are increasing the requirement for more diagnostic procedures which is boosting the market growth.
• Various technological advancements through various research which focus on improving the accuracy and reducing the pain of the patients are gaining significant importance in the biopsy needle market and are likely to increase the growth rate.
• The health infrastructure is gaining significant attention due to the increasing number of chronic medical conditions and the involvement of multiple companies. This is potentially creating opportunities for more new players.

Market Scope

Market Dynamics

Drivers

Upsurge in the number of cancer patients

The number of people suffering from cancer has increased rapidly over the past few years. Cancer is considered one of the diseases which has led to the second-greatest number of deaths. This has increased the number of people opting for diagnosis at early stages. The increasing number of individuals diagnosed with cancer has led to more tissue sampling to determine the type and stage of the disease. This has resulted in the increasing demand for more medical products including biopsy needles and related products. The biopsy needles play a vital role in the procedure where they help in obtaining the tissue and collecting the samples for molecular testing. The increasing geriatric population is considered to drive the growth of the market as they are more prone to such medical conditions.

Increasing preference for minimal invasive procedures (MIP)

The biopsy needle market is witnessing exponential growth due to the rise of patients preferring MIPs. These procedures have a significant benefit where they help in reducing the pain during biopsies compared to traditional surgeries. The minimal invasive procedures give better cosmetic outcomes as they create smaller puncture marks which reduces the risk of bleeding and other infections. This results in lower costs of hospital stays and benefits the patient economically. The image-guided technologies like CT scans help in enhancing the procedure and give the best possible outcomes.

Restraint

High cost of biopsy devices

The high costs of equipment make the treatment expensive, especially for people with low incomes. This acts as a restraint for the biopsy market as it reduces access to technologies for poor people suffering from cancer, especially in poor countries. Developing countries with limited access to health infrastructure and less GDP may slow down the market growth as it would be hard for them to access such kinds of technologies.

Opportunities

Increasing technological advancements

The growth of the biopsy needle market is driven by various factors which include the technological advancements in the industry. Various research and development activities are working on providing accurate treatments which will ease the pain of the patient. Many companies are aiming to bring more precise needles which will help to make the process short and accurate. Invasive techniques are helping in reducing the recovery times which also reduces the risk of any complications and gives an accurate picture of the patient's health.

The needles are optimized for breast and bone biopsies which will enhance the outcomes in these applications which will create opportunities for niche market penetration. The investments of many governments in companies are increasing the opportunities for many new players to step into the market and increase the market growth.

The rising awareness among the geriatric population

The rapid increase in the adult population has increased the risk of becoming more prone to developing conditions like cancer. This is resulting in more adults opting for cancer tests which might help them detect the disease at an early stage and start immediate treatment. Needle biopsies play a vital role in identifying the disease which increases the demand for medical products needed in biopsy. This also results in the demand for more research and development activity which might help to bring more convenient options for the aged patients. Thus, increasing awareness among the geriatric population will potentially help drive market growth and provide opportunities for new players.

Product Insights

The needle biopsy guns segment dominated the global biopsy needle market with the largest shares in 2023. The demand for biopsy guns has increased significantly due to the precise control and accuracy of biopsy guns. The technological advancements are minimizing the procedure which makes the treatment cost effective. Biopsy guns are in high demand due to the increasing number of cancer patients. These benefits are expected to maintain dominance of the biopsy guns over the forecast period. Many companies are focused on introducing more efficient biopsy guns which will potentially increase opportunities in the biopsy needle market.

The biopsy needles segment experienced decent growth in 2023 as they offer the service in different types of biopsies like vacuum-based biopsies, core needle biopsies, and many more. The needle growth is driven by the increasing number of patients opting for treatments at early stages. This opens the gates for many new market players to contribute to the market growth. According to the report studies, the increasing number of cancer patients will drive the market growth substantially in the upcoming years.

Application Insights

The cancer segment dominated the biopsy needle market with the largest revenue share in 2023. The increasing number of breast cancer, lung cancer and prostate cancer patients is increasing the demand for cancer treatments including biopsies. The procedure includes obtaining tissue samples from the targeted area of the patient and helping them to detect the stage and type of their disease. The increasing number of cancer patients results in demand for more convenient treatment options for cancer. The cancer segment is expected to dominate the biopsy needle market due to the increasing number of people opting for treatment at early stages.

The autoimmune disorder segment is expected to witness greater growth with the rising number of conditions like type-1 diabetes, celiac disease, psoriatic arthritis and many more. The increasing healthcare infrastructure and technological advancements are likely to drive market growth as they match the public demand with convenient treatments.

End-user Insights

The hospitals segment dominated the biopsy needle market with the largest share in 2023. Hospitals play a vital role in the growth of the market as they provide numerous medical facilities including diagnostic procedures under professional supervision. The industry has easier connections with the hospitals as they help in increasing their supply chain and expand their business. The hospitals provide specialized professionals under every department which makes the process easier and reliable for the patient. The hospital segment is expected to dominate the market as many governments are focusing on the development of healthcare infrastructure.

The ambulatory surgical centers segment is witnessing rapid growth as these centers provide short and effective treatments which reduces the costs and avoids the overnight stays. The surgical centres are growing at a faster rate as the focus towards providing various medical services is increasing. The demand for more convenient treatment could potentially drive the growth of ambulatory surgical centers.

Biopsy Needle Market Companies

• Becton
• Medtronic Plc
• Cardinal Health
• Hologic Inc
• Olympus Corporation
• Argon Medical Devices Inc
• Devicor Medical Products, Inc
• B. Braun Melsungen AG
• Cook Group Incorporated
• Boston Scientific Corporation
• FUJIFILM Holdings Corporation
• Dickinson and Company
• Stryker Corporation
• INRAD, Inc

Recent Developments

• In 2022, Cambridge Enterprise introduced their biopsy device named ‘CamPROBE’. The prostate biopsy device aims to reduce the risks related to conventional transrectal biopsies.
• In 2022, Mammatome introduced their dual-core biopsy system which marked their first step in the core biopsy market. The device reduces the vibrations and needle movements and helps to enhance the patient experience.
• In 2022, Limaca Medical received its breakthrough device through the FDA for its Precision-GI endoscopic ultrasound biopsy needle. The invention aims to reduce issues like blood contamination, tissue fragmentation, and less collection of sample quantity during the entire procedure.
• In 2021, Hologic Inc. acquired a company named Somatex Technologies for 64 million, aiming to increase the treatment offerings for breast cancer.

Segments Covered in the Report

By Product

• Biopsy Needle Guns
  • Vacuum-assisted Biopsy Devices
  • Fine Needle Aspiration Biopsy
  • Core Needle Biopsy Devices
• Biopsy Needles
  • Disposable
  • Reusable

By Application

• Cancer
  • Breast
  • Lung
  • Prostate
  • Colon
  • Stomach
  • Liver
  • Other cancer
• Autoimmune Disorder
• Infectious Diseases
• Others

By End-use

• Hospitals
• Ambulatory Surgical Centers
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa